Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 09:02 am Purchase |
2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Lynx1 Capital Management LP | 10,874,723 5.200% |
10,874,723 (New Position) |
Filing History |
| 2025-02-14 09:01 am Purchase |
2024-12-31 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 9,256,953 15.000% |
829,998 (+9.85%) |
Filing History |
| 2025-02-14 09:01 am Purchase |
2024-12-31 | 13G | Precision BioSciences, Inc. DTIL |
Lynx1 Capital Management LP | 766,051 9.990% |
766,051 (New Position) |
Filing History |
| 2025-02-14 09:00 am Purchase |
2024-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
Lynx1 Capital Management LP | 5,357,347 10.900% |
132,747 (+2.54%) |
Filing History |
| 2025-02-10 5:29 pm Purchase |
2025-02-06 | 13G | GH Research PLC GHRS |
Lynx1 Capital Management LP | 6,353,069 10.200% |
1,494,075 (+30.75%) |
Filing History |
| 2025-02-10 5:22 pm Purchase |
2024-12-31 | 13G | GH Research PLC GHRS |
Lynx1 Capital Management LP | 4,858,994 9.300% |
663,100 (+15.80%) |
Filing History |
| 2024-11-14 09:07 am Sale |
2024-09-30 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Lynx1 Capital Management LP | 37,436 2.800% |
-84,762 (-69.36%) |
Filing History |
| 2024-11-14 09:05 am Purchase |
2024-09-30 | 13G | GH Research PLC GHRS |
Lynx1 Capital Management LP | 4,195,894 8.100% |
1,201,835 (+40.14%) |
Filing History |
| 2024-11-14 09:03 am Sale |
2024-09-30 | 13G | Bionomics Limited BNOX |
Lynx1 Capital Management LP | 8,245,095 3.200% |
-4,119,480 (-33.32%) |
Filing History |
| 2024-11-14 09:01 am Purchase |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
Lynx1 Capital Management LP | 6,880,527 9.900% |
3,746,131 (+119.52%) |
Filing History |
| 2024-11-14 09:00 am Purchase |
2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK |
Lynx1 Capital Management LP | 5,187,191 9.900% |
2,230,273 (+75.43%) |
Filing History |
| 2024-08-09 5:15 pm Purchase |
2024-08-07 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 8,426,955 13.600% |
3,581,084 (+73.90%) |
Filing History |
| 2024-04-01 7:23 pm Purchase |
2024-03-26 | 13G | iBio, Inc. IBIO |
Lynx1 Capital Management LP | 878,492 9.990% |
878,492 (New Position) |
Filing History |
| 2024-03-29 4:15 pm Purchase |
2024-03-19 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 4,845,871 8.700% |
4,466,712 (+1178.06%) |
Filing History |
| 2024-02-16 4:57 pm Purchase |
2024-02-06 | 13G | GH Research PLC GHRS |
Lynx1 Capital Management LP | 2,994,059 5.800% |
2,994,059 (New Position) |
Filing History |
| 2024-02-14 09:22 am Purchase |
2023-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN |
Lynx1 Capital Management LP | 3,813,926 6.600% |
687,753 (+22.00%) |
Filing History |
| 2024-02-14 09:21 am Sale |
2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Lynx1 Capital Management LP | 1,997,006 4.200% |
-216,172 (-9.77%) |
Filing History |
| 2024-02-14 09:21 am Sale |
2023-12-31 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 379,159 0.700% |
-2,976,758 (-88.70%) |
Filing History |
| 2024-02-14 09:21 am Purchase |
2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
Lynx1 Capital Management LP | 3,134,396 6.400% |
12,177 (+0.39%) |
Filing History |
| 2024-02-14 09:20 am Purchase |
2023-12-31 | 13G | Stoke Therapeutics, Inc. STOK |
Lynx1 Capital Management LP | 2,956,918 6.600% |
292,760 (+10.99%) |
Filing History |